Prkag1 Antibody

What is PRKAG1 and what are its primary functions?

PRKAG1 is a regulatory subunit of the AMP-activated protein kinase (AMPK) complex, officially known as "protein kinase, AMP-activated, gamma 1 non-catalytic subunit." The protein has a calculated molecular weight of 38 kDa but is typically observed at 35-38 kDa in experimental conditions . Recent research indicates that PRKAG1 (also referred to as AMPKγ1) plays a crucial role in tissue homeostasis and longevity pathways, particularly in response to nutritional status .

The protein contains 331 amino acids with key functional domains that facilitate its regulatory activity. PRKAG1 demonstrates important tissue-specific expression patterns that are particularly relevant in the context of aging research, where selective activation of the AMPK γ1 complex appears to sustain tissue homeostasis late in life and promotes longevity .

Which sample types have been validated for PRKAG1 antibody detection?

PRKAG1 antibodies have been successfully validated across multiple human sample types:

For optimal results with tissue samples, researchers should perform antigen retrieval with TE buffer pH 9.0, though citrate buffer pH 6.0 can serve as an alternative in some cases .

What are the recommended applications and dilutions for PRKAG1 antibody use?

Optimal antibody performance depends on appropriate dilution for specific applications:

These values should be considered starting points, as optimal dilution may be sample-dependent. It is strongly recommended that researchers titrate the antibody in each testing system to obtain optimal results for their specific experimental setup .

What are the proper storage and handling conditions for PRKAG1 antibodies?

PRKAG1 antibodies should be stored at -20°C where they remain stable for one year after shipment. The typical storage buffer contains PBS with 0.02% sodium azide and 50% glycerol at pH 7.3 . For smaller volumes (20μl), preparations may contain 0.1% BSA.

How can researchers verify PRKAG1 antibody specificity?

Verification of antibody specificity is crucial for generating reliable experimental data. Multiple approaches include:

• Knockout/Knockdown Validation: Several publications have used PRKAG1 knockdown models for antibody validation .

• Western Blot Profile Analysis: A specific PRKAG1 antibody should produce a clean band at 35-38 kDa with minimal non-specific binding.

• Cross-Reactivity Testing: While designed for human samples, some PRKAG1 antibodies show cross-reactivity with mouse and rat samples, allowing for comparative studies .

• Multi-application Validation: Confirming detection across different techniques (WB, IHC, IF) in the same samples increases confidence in specificity.

• Peptide Competition Assays: Pre-incubation with the immunizing peptide should abolish specific signals.

How does PRKAG1 expression change with aging in different tissues?

Recent studies show significant tissue-specific changes in PRKAG1 expression with aging:

• Subcutaneous Adipose Tissue (SAT): PRKAG1 expression significantly decreases with age .

• Blood Cells: Shows substantial age-related PRKAG1 downregulation, making it an especially valuable tissue for aging studies .

• Heart: Decreased PRKAG1 expression observed in both sexes with advancing age .

• Liver: Significant age-related decrease observed specifically in males .

This contrasts with PRKAG2 (γ2 subunit), which significantly increases with age only in SAT, highlighting the distinct roles of different AMPK gamma subunits in the aging process . These expression patterns appear to be nutritionally regulated, with fasting generally upregulating PRKAG2 and downregulating PRKAG1, though with tissue-specific variations .

What methodological approaches should researchers use when studying PRKAG1 in aged tissue samples?

When investigating PRKAG1 in aged tissue samples, researchers should consider several methodological aspects:

• Normalization Strategy: Age-related changes in housekeeping genes necessitate careful selection of normalization controls. Multiple reference genes are recommended.

• Sample Collection Timing: PRKAG1 expression demonstrates nutritional-dependent variation, so standardizing the feeding/fasting state is critical for comparative studies .

• Tissue Preparation: Aged tissues often contain more fibrous material and altered fat composition, requiring modified extraction protocols.

• Antigen Retrieval Optimization: For IHC/IF in aged tissues, extended antigen retrieval may be necessary. Testing both TE buffer pH 9.0 and citrate buffer pH 6.0 is recommended to determine optimal conditions .

• Quantification Approaches: qPCR for mRNA expression has been successfully used in human cohort studies, while protein-level studies should account for potential post-translational modifications that may change with age .

How does PRKAG1 expression correlate with measures of health and frailty in humans?

Research has revealed significant correlations between PRKAG1 expression and health metrics in elderly populations:

• Multidimensional Prognostic Index (MPI): PRKAG1 expression in PBMCs is inversely correlated with MPI score, which predicts mortality risk in older individuals. This relationship exists independent of chronological age within later life stages (65-90 years) .

• Specific Health Components: PRKAG1 expression shows significant negative correlation with:

  • Cumulative Illness Rating Scale–Comorbidity Index (CIRS–CI)

  • Number of medications (NM)

• Functional Parameters: PRKAG1 expression positively correlates with:

  • Mini Nutritional Assessment (MNA)

  • Activities of Daily Living (ADL)

  • Instrumental Activities of Daily Living (IADL)

  • Exton Smith Scale (ESS)

These correlations indicate that higher PRKAG1 expression is associated with reduced multimorbidity and improved nutritional status and functional skills in older individuals. Importantly, these relationships appear specific to PRKAG1, as PRKAG2 expression was not associated with any MPI components .

What are the technical challenges in detecting PRKAG1 in different experimental contexts?

Researchers face several technical challenges when detecting PRKAG1:

• Tissue-Specific Expression Levels: Expression varies significantly across tissues, requiring optimization of protein loading and antibody concentrations for each tissue type.

• Age-Related Modifications: Post-translational modifications or splicing variants that may change with age can affect antibody epitope recognition.

• Nutritional State Influence: PRKAG1 expression is affected by nutritional status, necessitating standardized feeding/fasting protocols for comparative studies .

• Cross-Reactivity Concerns: While antibodies may potentially cross-react with other AMPK γ subunits (particularly γ2 and γ3), published protocols have successfully differentiated between these subunits .

• Signal Amplification Requirements: In tissues with low expression, particularly aged tissues, signal amplification techniques may be necessary while maintaining specificity.

What are the latest findings regarding PRKAG1's role in longevity pathways?

Recent research has identified PRKAG1 as a key player in longevity and healthy aging:

• Refeeding Response: PRKAG1 has been identified as part of a refeeding-associated complex that sustains tissue homeostasis late in life and promotes longevity .

• Nutritional Dependency: PRKAG1 expression demonstrates nutritional-dependent patterns, with differential regulation during fasting and refeeding states .

• Aging Biomarker: PRKAG1 expression in blood cells shows potential as a biomarker for healthy aging, independent of chronological age in older adults .

• Functional Relevance: The relationship between PRKAG1 expression and health metrics appears specific rather than a consequence of general changes in gene expression due to disease, highlighting its potential functional significance in aging processes .

• Tissue Homeostasis: Selective activation of the AMPK γ1 complex appears to be a mechanism for maintaining tissue homeostasis during aging, suggesting a potential therapeutic target for age-related conditions .

How should researchers interpret contradictory results when using PRKAG1 antibodies?

When facing contradictory results with PRKAG1 antibodies, researchers should consider:

• Antibody Clone Variations: Different antibody clones target distinct epitopes, potentially yielding different results. The antibody's recognition site (e.g., AA 1-247 vs. AA 230-331) can affect detection patterns .

• Technical Protocol Differences: Variations in sample preparation, antigen retrieval methods, or detection systems can significantly impact results.

• Biological Variables:

  • Age of subjects/samples

  • Nutritional status at collection time

  • Tissue-specific expression patterns

  • Sex-specific differences (particularly in liver)

• Validation Approaches:

  • Use multiple antibodies targeting different epitopes

  • Employ complementary techniques (protein vs. mRNA detection)

  • Include appropriate positive and negative controls

  • Verify with genetic models (knockout/knockdown)

• Standardization Recommendations: Methodological standardization across studies is essential, particularly regarding feeding/fasting states when studying PRKAG1 due to its nutritional responsiveness .